Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 1,200 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 52.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,480 shares of the medical research company’s stock after acquiring an additional 1,200 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Bio-Rad Laboratories were worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Venturi Wealth Management LLC raised its position in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the period. Gladius Capital Management LP bought a new position in shares of Bio-Rad Laboratories in the third quarter valued at about $32,000. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at about $33,000. UMB Bank n.a. raised its position in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in Bio-Rad Laboratories during the third quarter worth about $55,000. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Trading Down 0.2 %

Shares of Bio-Rad Laboratories stock opened at $276.85 on Thursday. The company has a market capitalization of $7.75 billion, a price-to-earnings ratio of -4.26 and a beta of 0.90. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The firm’s 50-day moving average price is $329.49 and its two-hundred day moving average price is $333.37.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Wells Fargo & Company lowered their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.